ASXL1基因c.1934dup；p.Gly646Trpfs*12——一种需要新方法应对的真正体细胞改变。 - Suppr

ASXL1 c.1934dup;p.Gly646Trpfs*12-a true somatic alteration requiring a new approach.

作者信息

Yannakou Costas K, Jones Kate, McBean Michelle, Thompson Ella R, Ryland Georgina L, Doig Ken, Markham John, Westerman David, Blombery Piers

机构信息

Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.

University of Melbourne, Parkville, VIC, 3010, Australia.

出版信息

Blood Cancer J. 2017 Dec 15;7(12):656. doi: 10.1038/s41408-017-0025-8.

DOI:10.1038/s41408-017-0025-8

PMID:29242575

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5802455/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb87/5802455/1fe23959513a/41408_2017_25_Fig1_HTML.jpg

相似文献

ASXL1 c.1934dup;p.Gly646Trpfs*12-a true somatic alteration requiring a new approach.

Blood Cancer J. 2017 Dec 15;7(12):656. doi: 10.1038/s41408-017-0025-8.

Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS.

Leukemia. 2018 Aug;32(8):1874-1878. doi: 10.1038/s41375-018-0193-y. Epub 2018 Jun 29.

Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era.

PLoS One. 2018 Sep 17;13(9):e0204218. doi: 10.1371/journal.pone.0204218. eCollection 2018.

Familial hematological malignancies: ASXL1 gene investigation.

Clin Transl Oncol. 2016 Apr;18(4):385-90. doi: 10.1007/s12094-015-1379-7. Epub 2015 Aug 19.

Highly variable mutational profile of ASXL1 in myelofibrosis.

Eur J Haematol. 2016 Oct;97(4):331-5. doi: 10.1111/ejh.12731. Epub 2016 Jan 19.

Somatic mutation of CYLD gene is rare in hematologic and solid malignancies.

Leuk Res. 2011 Jul;35(7):e136-7. doi: 10.1016/j.leukres.2011.02.024. Epub 2011 Mar 21.

mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies.

Commun Biol. 2021 Mar 29;4(1):424. doi: 10.1038/s42003-021-01938-0.

Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels.

Exp Hematol. 2016 Mar;44(3):172-6.e1. doi: 10.1016/j.exphem.2015.11.011. Epub 2015 Dec 15.

ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.

Br J Haematol. 2010 Nov;151(4):365-75. doi: 10.1111/j.1365-2141.2010.08381.x. Epub 2010 Sep 29.

The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration.

Leukemia. 2010 Sep;24(9):1656-7. doi: 10.1038/leu.2010.144. Epub 2010 Jul 1.

引用本文的文献

ASXL1 mutation-related clonal hematopoiesis and age-related diseases: clinical evidence and molecular insights.

Int J Hematol. 2025 Aug 7. doi: 10.1007/s12185-025-04038-5.

Cell Rep Med. 2024 Dec 17;5(12):101835. doi: 10.1016/j.xcrm.2024.101835. Epub 2024 Dec 2.

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.

Leukemia. 2023 Nov;37(11):2150-2167. doi: 10.1038/s41375-023-02048-y. Epub 2023 Oct 4.

A reappraisal of ASXL1 mutation sites and the cohesin-binding motif in myeloid disease.

Blood Cancer J. 2023 Jun 26;13(1):96. doi: 10.1038/s41408-023-00876-w.

Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia.

Ann Lab Med. 2023 Jul 1;43(4):328-336. doi: 10.3343/alm.2023.43.4.328. Epub 2023 Feb 24.

Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm.

Cancers (Basel). 2021 Nov 23;13(23):5888. doi: 10.3390/cancers13235888.

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.

Blood Cancer J. 2021 Sep 21;11(9):157. doi: 10.1038/s41408-021-00541-0.

Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia.

Am J Hematol. 2021 Apr 1;96(4):462-470. doi: 10.1002/ajh.26110. Epub 2021 Feb 15.

Clonal independence of and or mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing.

Haematologica. 2021 Jan 1;106(1):313-315. doi: 10.3324/haematol.2020.260448.

Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS.

Leukemia. 2018 Aug;32(8):1874-1878. doi: 10.1038/s41375-018-0193-y. Epub 2018 Jun 29.

本文引用的文献

Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.

Arch Pathol Lab Med. 2017 Jun;141(6):759-775. doi: 10.5858/arpa.2016-0547-RA. Epub 2017 Mar 9.

Coming of age: ten years of next-generation sequencing technologies.

Nat Rev Genet. 2016 May 17;17(6):333-51. doi: 10.1038/nrg.2016.49.

BAP1/ASXL1 recruitment and activation for H2A deubiquitination.

Nat Commun. 2016 Jan 7;7:10292. doi: 10.1038/ncomms10292.

Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia.

N Engl J Med. 2015 Jul 2;373(1):35-47. doi: 10.1056/NEJMoa1414799.

N Engl J Med. 2014 Dec 25;371(26):2488-98. doi: 10.1056/NEJMoa1408617. Epub 2014 Nov 26.

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.

Leukemia. 2014 Nov;28(11):2206-12. doi: 10.1038/leu.2014.125. Epub 2014 Apr 3.

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

J Clin Oncol. 2013 Jul 1;31(19):2428-36. doi: 10.1200/JCO.2012.47.3314. Epub 2013 May 20.

Mutations and prognosis in primary myelofibrosis.

Leukemia. 2013 Sep;27(9):1861-9. doi: 10.1038/leu.2013.119. Epub 2013 Apr 26.

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.

Leukemia. 2013 Jan;27(1):82-91. doi: 10.1038/leu.2012.262. Epub 2012 Sep 11.

ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.

Cancer Cell. 2012 Aug 14;22(2):180-93. doi: 10.1016/j.ccr.2012.06.032.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

ASXL1 c.1934dup;p.Gly646Trpfs*12-a true somatic alteration requiring a new approach.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献